Evidence map›Paper›PMID 37359780›Full record

ArticleNefrologia : publicacion oficial de la Sociedad Espanola Nefrologia2023

[Characterization of hospitalized patients with acute kidney injury associated with COVID-19 in Spain: Renal replacement therapy and mortality. FRA-COVID SEN Registry Data].

Mercedes Salgueira, Marina Almenara, Antonio Gutierrez-Pizarraya, Lara Belmar, Pedro Jesús Labrador, Rosa Melero, María Luisa Serrano, José María Portolés, Alicia Molina, Esteban Poch and 7 more

Abstract readEnglish Abstract
In one paragraph

Article in Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mercedes SalgueiraUnidad de Nefrología, Hospital Universitario Virgen Macarena, Sevilla, España.
Marina AlmenaraUnidad de Nefrología, Hospital Universitario Virgen Macarena, Sevilla, España.
Antonio Gutierrez-PizarrayaUnidad de Nefrología, Hospital Universitario Virgen Macarena, Sevilla, España.
Lara BelmarUnidad de Nefrología, Hospital Universitario Marqués de Valdecilla, Santander, España.
Pedro Jesús LabradorUnidad de Nefrología, Complejo Hospitalario Universitario de Cáceres, Cáceres, España.
Rosa MeleroUnidad de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España.
María Luisa SerranoUnidad de Nefrología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España.
José María PortolésUnidad de Nefrología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España.
Alicia MolinaUnidad de Nefrología, Hospital Clinic, Barcelona, España.
Esteban PochUnidad de Nefrología, Hospital Clinic, Barcelona, España.
Natalia RamosUnidad de Nefrología, Hospital Vall d'Hebron, Barcelona, España.
María Jesús LloretUnidad de Nefrología, Fundació Puigvert, Barcelona, España.
Rocío EcharriUnidad de Nefrología, Hospital Universitario Infanta Sofía, Madrid, España.
Raquel Díaz ManceboUnidad de Nefrología, Hospital Universitario Infanta Sofía, Madrid, España.
Diego Mauricio González-LaraUnidad de Nefrología, Complejo Hospitalario Universitario de Toledo, Toledo, España.
Jesús Emilio SánchezUnidad de Nefrología, Hospital Universitario de Cabueñes, Gijón, España.
María José SolerUnidad de Nefrología, Hospital Vall d'Hebron, Barcelona, España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objectives: Acute kidney injury (AKI) is common among hospitalized patients with COVID-19 and associated with worse prognosis. The Spanish Society of Nephrology created the AKI-COVID Registry to characterize the population admitted for COVID-19 that developed AKI in Spanish hospitals. The need of renal replacement therapy (RRT) therapeutic modalities, and mortality in these patients were assessed. Material and method: In a retrospective study, we analyzed data from the AKI-COVID Registry, which included patients hospitalized in 30 Spanish hospitals from May 2020 to November 2021. Clinical and demographic variables, factors related to the severity of COVID-19 and AKI, and survival data were recorded. A multivariate regression analysis was performed to study factors related to RRT and mortality. Results: Data from 730 patients were recorded. A total of 71.9% were men, with a mean age of 70 years (60-78), 70.1% were hypertensive, 32.9% diabetic, 33.3% with cardiovascular disease and 23.9% had some degree of chronic kidney disease (CKD). Pneumonia was diagnosed in 94.6%, requiring ventilatory support in 54.2% and admission to the ICU in 44.1% of cases.The median time from the onset of COVID-19 symptoms to the appearance of AKI (37.1% KDIGO I, 18.3% KDIGO II, 44.6% KDIGO III) was 6 days (4-10). A total of 235 (33.9%) patients required RRT: 155 patients with continuous renal replacement therapy, 89 alternate-day dialysis, 36 daily dialysis, 24 extended hemodialysis and 17 patients with hemodiafiltration. Smoking habit (OR 3.41), ventilatory support (OR 20.2), maximum creatinine value (OR 2.41) and time to AKI onset (OR 1.13) were predictors of the need for RRT; age was a protective factor (0.95). The group without RRT was characterized by older age, less severe AKI, shorter kidney injury onset and recovery time ( Conclusions: Patients with AKI during hospitalization for COVID-19 had a high mean age, comorbidities and severe infection. We defined two different clinical patterns: an AKI of early onset, in older patients that resolves in a few days without the need for RRT; and another more severe pattern, with greater need for RRT, and late onset, which was related to greater severity of the infectious disease. The severity of the infection, age and the presence of CKD prior to admission were identified as risk factors for mortality in these patients. In addition chronic treatment with ARBs was identified as a protective factor for mortality.

Indexed as

Acute kidney injuryCOVID-19HemodialysisRenal replacement therapySARS-CoV-2

Identifiers

PMID37359780
PMCPMC10076078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.